Tiny Health has raised $33 million in an oversubscribed Series B round, bringing its total funding to $46 million. The Austin-based company plans to use the financing to advance clinical research, expand healthcare practitioner education and grow Powered by Tiny, its platform for healthcare and consumer health partners.
Alongside the financing, Tiny Health announced a $5 million Microbiome Research Program that will provide researchers and clinicians with access to its testing, data and research capabilities.
Tiny Health offers gut microbiome testing for babies, children and adults, alongside vaginal microbiome tests. Its technology uses shotgun metagenomic sequencing to identify microorganisms within samples and generate information intended to help consumers and healthcare practitioners understand microbiome patterns.
The company is also developing TinyAI, a tool designed to provide guidance based on individual test results and Tiny Health’s microbiome dataset. Powered by Tiny extends the company’s testing and analysis capabilities to healthcare partners.
“This raise will allow us to put $5 million toward the creation of a Microbiome Research Program, focused on supporting interventional studies that can help us understand how microbiome interventions can improve health outcomes,” founder and CEO Cheryl Sew Hoy said.
Practitioner education is another focus. Hoy noted that most physicians are not trained to interpret microbiome reports, “so we've built an in-house clinical education team solely focused on teaching providers how to interpret our gut and vaginal microbiome tests and integrate them into their existing workflow,” she said.
Tiny Health also aims to make microbiome research infrastructure more accessible to independent researchers and practitioners. “We want to remove that barrier and help practitioners, academic researchers and companies incorporate high-quality microbiome data into interventions they're developing,” Hoy said.
The funding comes amid broader investment in microbiome-focused healthcare companies. Evvy recently raised $40 million to expand its vaginal microbiome platform, while Viome and Salvo Health have also secured funding to develop testing, diagnostics and digestive health services.
Click here for the original news story.
